For measurement of parathyroid hormone (PTH), the intact PTH (I-PTH) assay is generally used. However, I-PTH assay apparently detects PTH 7-84 fragments, in addition to PTH 1-84. The whole PTH (W-PTH) assay exhibits no cross-reactivity with PTH 7-84. Ratio of PTH 1-84 to non-(1-84) PTH has been proposed as a non-invasive indicator of bone turnover in patients with end-stage renal disease (ESRD)...

For measurement of parathyroid hormone (PTH), the intact PTH (I-PTH) assay is generally used. However, I-PTH assay apparently detects PTH 7-84 fragments, in addition to PTH 1-84. The whole PTH (W-PTH) assay exhibits no cross-reactivity with PTH 7-84. Ratio of PTH 1-84 to non-(1-84) PTH has been proposed as a non-invasive indicator of bone turnover in patients with end-stage renal disease (ESRD)...

INTRODUCTION The aim of this study was to determine the factors, including markers of bone resorption and bone formation, which determine catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis (RA). METHODS Forty RA patients received high-resolution peripheral quantitative computed tomography (HR-pQCT) analysis of the metacarpophalangeal joints II and III of t...

Bone metabolism changes in patients with inflammatory bowel disease (IBD) awoke a growing interest in the past few years mostly because of their high prevalence, with estimations around 40-50% for osteopenia and 530% regarding osteoporosis (1-3). The presence of bone metabolism changes in these patients is an issue of great clinical relevance given an increased risk for bone fracture, primarily...

BACKGROUND Hepatic osteodystrophy occurs in the majority of patients with advanced chronic liver disease with the abnormalities in bone metabolism accelerating following orthotopic liver transplantation (OLT). AIMS To examine changes in bone mineral density (BMD) following OLT and to investigate factors that lead to bone loss. METHODS Twelve patients had BMD (at both the lumbar spine (LS) a...

BACKGROUND Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. PATIENTS AND METHODS The bone formation marker serum osteocalcin, the bone resorption marker serum carboxyterminal telopeptide of type I collagen (CTx), serum parathyroid hormone (PTH), 25-...

In the last few years, research on the use of biochemical markers of bone turnover has greatly improved. Among the several available bone turnover markers, monitoring serum C-terminal cross-linked telopeptides is one of the most accurate one. Manual and automated immunoassays are available for the measurement of CTX, which show high analytical performance. However, they are very expensive, time...

The occurrence of drug-induced osteonecrosis the jaw in cancer patients treated using bone-modifying medications (bisphosphonates and denosumab) is a highly relevant research problem studied by dentists, maxillofacial surgeons, oncologists. Despite large number publications, practical approaches to preventing remain be developed, which confirmed increasing prevalence severity clinical course di...